---
title: "Popular Drug Maker Slams GLP-1 Peer on False Advertising"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293350297.md"
description: "Novo Nordisk filed a lawsuit against rival Eli Lilly, alleging misleading advertising for its GLP-1 drugs and demanding an apology and corrective measures. This follows a previous dispute with Hims & Hers Health. Meanwhile, Novo Nordisk stock is down 1% to $49.14, trading near the $50 level. Despite bearish broker recommendations, put/call ratios suggest potential bullish sentiment, and high volatility scores indicate options may be underpricing recent price swings."
datetime: "2026-07-21T13:35:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293350297.md)
  - [en](https://longbridge.com/en/news/293350297.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293350297.md)
---

# Popular Drug Maker Slams GLP-1 Peer on False Advertising

**Novo Nordisk (NYSE:NVO)** stock is down 1% at $49.14, after the drugmaker filed a lawsuit against rival Eli Lilly (LLY), citing misleading advertising for its GLP-1 drugs. The company said it wants Lilly to issue an apology and corrective advertising. Novo also had a **GLP-1 dispute** with Hims & Hers Health (HIMS) earlier this year.

NVO is below its year-to-date breakeven level, an area that roughly coincides with its 320-day moving average. The shares have been consolidating near the $50 level this month, which NVO hasn't seen since February.

Plus, bulls have been circling. This is per the 10-day put/call volume ratio of 6.82 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which ranks in the 78th percentile of its annual range. Echoing this, Novo Nordisk's Schaeffer's put/call open interest ratio (SOIR) of 0.74, which sits in the 92nd percentile of its annual range.

There remains plenty of room for upgrades, should the heavily bearish sentiment begin to unwind. Heading into today, 21 of the 23 brokerages in coverage sport a "hold" or "strong sell" recommendation.

The equity sports an **Schaeffer's Volatility Scorecards (SVS)** reading of 98 out of 100, suggesting NVO has realized higher volatility than its options have priced in over the past 12 months.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [NVOH.US](https://longbridge.com/en/quote/NVOH.US.md)
- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)

## Related News & Research

- [Novo CEO says obesity market won't be winner-take-all battle with Lilly](https://longbridge.com/en/news/295777893.md)
- [Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient](https://longbridge.com/en/news/296005917.md)
- [Community Financial Services Group LLC Acquires 1,774 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/295504105.md)
- [Novo Nordisk A/S - share repurchase programme | NVO Stock News](https://longbridge.com/en/news/295416078.md)
- [Lilly, Novo defeat antitrust lawsuit over GLP‑1 drug market](https://longbridge.com/en/news/295148841.md)